Head-to-head · WeighScore
Alloy vs Omada Health
The verdict
Alloy takes it — 72.2/100 to 55.6/100.
Alloy grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Alloy is a menopause-focused telehealth brand whose Weight Care program runs the broadest GLP-1 formulary in our catalog — brand Wegovy, brand Zepbound, oral Wegovy, plus compounded semaglutide, tirzepatide…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Alloy | Omada Health |
|---|---|---|
| WeighScore | 72.2/100 | 55.6/100 |
| Grade | C | C |
| Scorecard rank | #80 | #435 |
| Semaglutide | $169/mo (compounded) | Not disclosed |
| Tirzepatide | $199/mo (compounded) | Not disclosed |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #80 · C
Strengths
- Broadest GLP-1 formulary here: brand Wegovy and Zepbound, oral Wegovy, plus compounded semaglutide, tirzepatide, and liraglutide
- All consulting doctors are certified by The Menopause Society — a rare credential
- STARTGLP1 promo code takes $50 off the first month
- Spans the price range: compounded semaglutide from $70/mo, brand Wegovy from $199/mo (each plus the $99/mo Weight Care fee)
Where it loses points
- Menopause-focused — best for women in menopause or perimenopause, not men or younger patients
- A mandatory $99/mo Alloy Weight Care fee sits on top of every medication price (so the true minimum is ~$169/mo, not $70)
- Compounded semaglutide not available in AL, AR, CA, NV, LA, MS or DC
Graded #435 · C
Strengths
- Added GLP-1 prescribing and medication management in late 2025
- Clinicians trained in obesity care, available in all 50 states
- Behavioral support wrapped before, during and after treatment
- GLP-1 Flex Care adds a cash-pay medication pathway in 2026
- Publicly traded, evidence-based virtual care platform
Where it loses points
- Core program distributed via employers and health plans, limited cash-pay
- GLP-1 prescribing is a recent addition still scaling
- GLP-1 Flex Care only rolling out to employers later in 2026
- No transparent published price for the core member program
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.